Quick Takeaways: Why It Matters? Zoetis’ EC approval of Poulvac Procerta HVT-ND turns its single-dose, dual ND+Marek’s protection into a mainstream EU option, which should drive rapid adoption as producers shift from multi-vaccine schedules to a streamlined, in‑ovo or hatch-day protocol th...
Quick Takeaways: Why It Matters? By bringing real-time, cellular-level microscopic imaging into everyday veterinary workflows, without lab delays, InSpecta gives specialist, general, and mobile practices a new in‑house diagnostic capability that can speed decision-making and create billabl...
Quick Takeaways: Why It Matters? By pairing patented ProLong Technology, which bonds to gums and slowly releases active ingredients to control plaque and tartar, with a catnip flavor and “twist-and-lick” format, Tevra is positioning Vetality Brush Free Twist + Lick as a flagship product in...
Featured Article Cover Story Regulatory Updates Launch Product Launch PetMeds Receives New Acquisition Proposal Corporate transaction PetMed Express has received an unsolicited, non-binding proposal from SilverCape Investments to acquire all outstanding shares for $3.00 per share in cash. ...
Quick Takeaways: Why It Matters? ECO Animal Health’s EU launch of Ecovaxxin MS is a meaningful commercial milestone because it converts the company’s own R&D pipeline into a marketed product and gives it a differentiated position in poultry vaccines. With access to a market spanning mo...
Featured Article Cover Story Regulatory Updates Research Updates Product Launch Retail expansion Dechra Opens Global Headquarters in Boston Corporate update Dechra has opened its new global headquarters in Boston, strengthening its innovation footprint while supporting community programs t...
Quick Takeaways: Why It Matters? Dechra’s Boston HQ move and community-facing strategy signal how veterinary pharma is increasingly aligning with mainstream human health and life sciences ecosystems, not just traditional animal-health hubs, which could intensify competition for talent, par...
Quick Takeaways: Why It Matters? Jaguar’s NADA submission is a meaningful de-risking step for Canalevia-CA1, because full FDA approval would likely expand its commercial credibility beyond conditional use and make it easier to gain adoption in veterinary onc...
Featured Article Cover Story Research Updates Regulatory Approval Product Launches Elanco Launches $25 Million Venture Fund Innovation platform Elanco Animal Health plans to launch Elanco Ventures, a $25 million corporate venture platform to back early-stage animal health innovation. Key h...
The US FDA’s 2025 animal health approvals highlight a transformative year for veterinary medicine, with major advances spanning companion animal therapeutics, livestock productivity, poultry health, parasitic disease management, diagnostics, oncology, and genetic innovation. The latest wav...
